TEDCO, Maryland’s economic engine for technology companies, announced today its Builder Fund invested $100,000 in LASARRUS, who are researching and developing devices for improved patient monitoring and treatment. TEDCO’s Builder Fund invests in and provides executive support to Maryland-based technology companies run by entrepreneurs who demonstrate economic disadvantage.
The U.S. Food and Drug Administration today approved Relyvrio (sodium phenylbutyrate/taurursodiol) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease.
New Clinical Pharmacology Desktop Software Launched by Pumas-AI is Easier to Use and Compliant with Global Regulations
Pumas-AI, a science-first organization that turns data into life-saving decisions faster, announced today that it has launched Pumas-CP – a new clinical pharmacology platform for non-compartmental analysis (NCA), bioequivalence analysis, and pharmacokinetic and pharmacodynamic (PK/PD) modeling.
As more life science companies flock to the region a new challenge arises – how do we create a strong pipeline of local talent to support their needs? This pipeline not only includes the high concentration of experienced talent the BHCR is known for but entry-level employees and people without four-year degrees who can be trained on-the-job.
CraniUS LLC, an R&D company focused on building groundbreaking treatments for patients with chronic brain disease, today announced the closing of a $19.4 million Series A fundraising round.
MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announces the signing of a strategic platform license (SPL) with Vertex Pharmaceuticals Incorporated, a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases.
The UM BioPark is expanding in West Baltimore, with new laboratory space and state-of-the-art equipment to advance medical technology and the life sciences sector in Maryland.
This month, BD officially opened its new Innovation Center on the UM BioPark campus , which will give University of Maryland, Baltimore (UMB) students access to the company’s advanced diagnostic tools and allow them to provide feedback on new concepts and technology. Known as one of the largest global medical technology companies, BD’s new facility contains several sophisticated systems, including the BD COR™ PX/GX fully automated diagnostic system for infectious disease molecular testing, and the BD MAX™ System, which includes a variety of tests and an open system for new test development.
NextCure (Nasdaq: NXTC), a growing clinical-stage biotechnology company nestled in Beltsville, Maryland, is setting the example. The company works to create novel immunomedicines to treat cancer and other immune-related diseases, and if you’ve read some of BioBuzz’s previous stories you should know by now that when NextCure says they are committed to something, they truly are committed.
Besides having a heavy hand in advancing the field of genomic medicines and solidifying the foundation for what has become the bustling I-270 Biotech Corridor, it’s clear that HGS has also had a major impact on the lives of those who worked there. BioBuzz in collaboration with Kymanox and BioIT Solutions recently hosted a HGS reunion event at True Respite Brewing Co., bringing together over 140 alumni of the organization. Some attendees even came in from out of state to catch up with former colleagues and friends that they haven’t seen in years.
The seas have been rough this year for the biotech and life sciences market, with funding scarcity and layoffs abound. The BioHealth Capital Region (BHCR) has braced the storm, though, holding tight to its fourth-place ranking on the Genetic & Engineering News (GEN) Top 10 Biopharma Clusters list. Alex Phillipidus, Senior Business Editor for GEN, gave the update at the eighth annual BioHealth Capital Region Forum.